Compare Manchester United PLC (MANU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs BIO-TECHNE Corp — how do they compare? Manchester United PLC trades at $22.23 (market cap $3.74B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 3× Manchester United PLC's market cap, and Manchester United PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals.
| MANU | TECH | |
|---|---|---|
Market Cap | $3.74B | $11.24B |
Sector | Media | Health |
52-Week High | $23.53 | $72.29 |
52-Week Low | $15.10 | $43.31 |
Enterprise Value | $4.68B | $11.32B |
Dividend Yield | 1.26% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $21.63, down 1.28% on the day, with a bearish technical signal and negative profitability metrics including a net income margin of -2.65% and ROE of -6.36%. Recent news highlights stadium development progress and Champions League qualification, but revenue growth remains limited. Cash flow trends show volatile investing activities, with 2025 net cash flow at $12.56 million.
The outlook is mixed: analyst consensus leans Hold (60%) with potential from cost reductions and stadium plans, but persistent losses and high debt pose risks. Near-term catalysts include Q2 2026 earnings, yet structural challenges in revenue expansion and weak cash conversion temper upside potential for investors.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
